Significantly lower annual rates of neoplastic progression in short- compared to long-segment non-dysplastic Barrett’s esophagus: a systematic review and meta-analysis
- 2 April 2019
- journal article
- review article
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 51 (07) , 665-672
Abstract
Background Although shorter lengths of Barrett’s esophagus (BE) have been associated with a lower risk of neoplastic progression, precise estimates have varied, especially for non-dysplastic BE (NDBE) only. Therefore, current US guidelines do not provide specific recommendations on surveillance intervals based on BE length. We performed a systematic review and meta-analysis of the published literature to examine neoplastic progression rates of NDBE based on BE length. Methods PubMed, Cochrane, Google Scholar, and Embase were comprehensively searched. Studies reporting progression rates in patients with NDBE and > 1 year of follow-up were included. The number of patients progressing to esophageal adenocarcinoma (EAC) and high grade dysplasia (HGD)/EAC in individual studies and the mean follow-up were recorded to derive person-years of follow-up. Pooled rates of progression to EAC and HGD/EAC based on BE length (< 3 cm vs. ≥ 3 cm) were calculated. Results Of the 486 initial studies identified, 10 met the inclusion/exclusion criteria. These included a total of 4097 NDBE patients; 1979 with short-segment BE (SSBE; 10 773 person-years of follow-up) and 2118 with long-segment BE (LSBE; 12 868 person-years). The annual rates of progression to EAC were significantly lower for SSBE compared with LSBE: 0.06 % (95 % confidence interval 0.01 % – 0.10 %) vs. 0.31 % (0.21 % – 0.40 %), respectively; odds ratio (OR) 0.25 (0.11 – 0.56); P < 0.001, as were the rates for the combined endpoint (HGD/EAC): 0.24 % (0.09 % – 0.32 %) vs. 0.76 % (0.43 % – 0.89 %), respectively; OR 0.35 (0.21 – 0.58); P < 0.001. There was no significant heterogeneity among studies. Conclusion The results demonstrate significantly lower rates of neoplastic progression in NDBE patients with SSBE compared with LSBE. BE length can easily be used for risk stratification purposes for NDBE patients undergoing surveillance endoscopy and consideration should be given to tailoring surveillance intervals based on BE length in future US guidelines.Keywords
This publication has 16 references indexed in Scilit:
- Length of Barrett's oesophagus and cancer risk: implications from a large sample of patients with early oesophageal adenocarcinomaGut, 2015
- Risk of Esophageal Adenocarcinoma and Mortality in Patients With Barrett's Esophagus: A Systematic Review and Meta-analysisClinical Gastroenterology and Hepatology, 2010
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and ElaborationPLOS Medicine, 2009
- Low incidence of adenocarcinoma and high-grade intraepithelial neoplasia in patients with Barrett’s esophagus: a prospective cohort studyEndoscopy, 2008
- Frequency of Barrett’s neoplasia after initial negative endoscopy with biopsy: a long-term histopathological follow-up studyEndoscopy, 2006
- Laparoscopic treatment of Barrett’s esophagus: long-term resultsSurgical Endoscopy, 2006
- Audit of a Barrett's epithelium surveillance databaseEuropean Journal of Gastroenterology & Hepatology, 2004
- Screening and Surveillance for Barrett Esophagus in High-Risk Groups: A CostUtility AnalysisAnnals of Internal Medicine, 2003
- Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973–1995International Journal of Cancer, 2002
- Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countriesInternational Journal of Epidemiology, 2000